NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

$321.85

-1.72 (-0.53%)

(As of 11:04 AM ET)

Compare

Today's Range: $320.50
▼
$324.58
50-Day Range: $304.75
▼
$350.40
52-Week Range: $243.17
▼
$354.46

Volume: 283,291 shs
Average Volume: 1.24 million shs
Market Capitalization: $82.89 billion

P/E Ratio: 25.63
Dividend Yield: N/A
Price Target: $352.59

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 9.4% Upside
$353.87 Price Target
Short Interest: Healthy
1.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: -3.12
Upright™ Environmental Score
News Sentiment: 0.82
Based on 8 Articles This Week
Insider Trading: Selling Shares
$18.94 M Sold Last Quarter
Proj. Earnings Growth: 7.35%
From $13.06 to $14.02 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

475th out of 1,006 stocks

Pharmaceutical Preparations Industry

227th out of 492 stocks

1.3

Analyst's Opinion

Consensus Rating
Vertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $353.87, Vertex Pharmaceuticals has a forecasted upside of 9.4% from its current price of $323.57.
Amount of Analyst Coverage
Vertex Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.26% of the float of Vertex Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vertex Pharmaceuticals has recently decreased by 0.31%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Vertex Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vertex Pharmaceuticals does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vertex Pharmaceuticals has received a 37.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cystic fibrosis medication" product. See details.
Environmental Sustainability
The Environmental Impact score for Vertex Pharmaceuticals is -3.12.

2.7

News and Social Media Coverage

News Sentiment
Vertex Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Vertex Pharmaceuticals this week, compared to 10 articles on an average week.
Search Interest
Only 73 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
MarketBeat Follows
30 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,939,902.00 in company stock.
Percentage Held by Insiders
Only 0.40% of the stock of Vertex Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Vertex Pharmaceuticals are expected to grow by 7.35% in the coming year, from $13.06 to $14.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vertex Pharmaceuticals is 25.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vertex Pharmaceuticals is 25.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.22.
Price to Earnings Growth Ratio
Vertex Pharmaceuticals has a PEG Ratio of 3.04. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Vertex Pharmaceuticals has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

May 20, 2023 | marketbeat.com

MarketBeat Week in Review – 5/15 - 5/19 (VRTX)

Investors are battling stagflation as they wait for a recession, and the MarketBeat team continues to help you understand where to find opportunities

May 18, 2023 | marketbeat.com

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

June 1, 2023 | americanbankingnews.com

William Blair Initiates Coverage on Vertex Pharmaceuticals (NASDAQ:VRTX)

May 27, 2023 | americanbankingnews.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated at Westpark Capital

May 25, 2023 | finance.yahoo.com

2 Top Trends to Invest $5,000 in Right Now

May 24, 2023 | seekingalpha.com

Vertex: CF Focus, Potential To Alter Acute Pain Treatment Market Landscape

May 20, 2023 | americanbankingnews.com

Zacks Research Equities Analysts Raise Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 19, 2023 | americanbankingnews.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Coverage Initiated by Analysts at StockNews.com

May 17, 2023 | seekingalpha.com

Vertex Pharmaceuticals Rally Likely Not Over

May 16, 2023 | finance.yahoo.com

Vertex Pharmaceuticals Offers Value Despite Recent Gains

May 16, 2023 | finance.yahoo.com

Vertex Pharmaceuticals (NASDAQ:VRTX) shareholders have earned a 17% CAGR over the last five years

May 15, 2023 | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $352.59 Average Price Target from Brokerages

May 13, 2023 | seekingalpha.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at BofA Securities 2023 Health Care Conference (Transcript)

May 12, 2023 | msn.com

This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?

May 11, 2023 | americanbankingnews.com

Bastiano Sanna Sells 422 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

May 11, 2023 | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells $997,500.00 in Stock

May 10, 2023 | finance.yahoo.com

2 Cathie Wood Stocks That Can Get You Through Any Recession

May 10, 2023 | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Jeffrey M. Leiden Sells 879 Shares of Stock

May 10, 2023 | americanbankingnews.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Chairman Jeffrey M. Leiden Sells 1,125 Shares of Stock

May 8, 2023 | marketwatch.com

Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

May 7, 2023 | americanbankingnews.com

Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells $568,770.52 in Stock

May 6, 2023 | finance.yahoo.com

This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock

May 6, 2023 | americanbankingnews.com

Sanford C. Bernstein Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $363.00

May 5, 2023 | americanbankingnews.com

Brokers Issue Forecasts for Vertex Pharmaceuticals Incorporated's FY2023 Earnings (NASDAQ:VRTX)

May 5, 2023 | americanbankingnews.com

SVB Leerink Weighs in on Vertex Pharmaceuticals Incorporated's Q2 2023 Earnings (NASDAQ:VRTX)

See More Headlines

VRTX Price History

30 days | 90 days | 365 days | Advanced Chart

VRTX Company Calendar

Last Earnings: 5/01/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VRTX
CUSIP: 92532F10
CIK: 875320
Web: www.vrtx.com
Phone: (617) 341-6100
Fax: 617-576-2109
Employees: 4,800
Year Founded: 1989

Price Target and Rating

Average Stock Price Forecast: $353.87
High Stock Price Forecast: $456.00
Low Stock Price Forecast: $285.00
Forecasted Upside/Downside: +9.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): $12.56
Trailing P/E Ratio: 25.76
Forward P/E Ratio: 24.78
P/E Growth: 3.08
Net Income: $3.32 billion
Net Margins: 35.40%
Pretax Margin: 45.28%
Return on Equity: 25.06%
Return on Assets: 19.25%

Debt

Debt-to-Equity Ratio: 0.03
Current Ratio: 4.28
Quick Ratio: 4.11

Sales & Book Value

Annual Sales: $9.21 billion
Price / Sales: 9.05
Cash Flow: $13.72 per share
Price / Cash Flow: 23.59
Book Value: $56.04 per share
Price / Book: 5.77

Miscellaneous

Outstanding Shares: 257,552,000
Free Float: 256,779,000
Market Cap: $83.34 billion
Optionable: Optionable
Beta: 0.49

Social Links

Key Executives

Reshma Kewalramani
President, Chief Executive Officer & Director

Stuart A. Arbuckle
Chief Operating Officer & Executive Vice President

Charles F. Wagner
Chief Financial Officer & Executive Vice President

David Matthew Altshuler
Chief Scientific Officer & EVP-Global Research

Mark Bunnage
Senior Vice President & Head-Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.
What is Vertex Pharmaceuticals' stock price forecast for 2023?: 16 analysts have issued 12 month price objectives for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $285.00 to $456.00. On average, they expect the company's share price to reach $353.87 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.
How have VRTX shares performed in 2023?: Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX shares have increased by 12.0% and is now trading at $323.57.
View the best growth stocks for 2023 here.
When is Vertex Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our VRTX earnings forecast.
How were Vertex Pharmaceuticals' earnings last quarter?: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings results on Monday, May, 1st. The pharmaceutical company reported $3.05 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.54. The pharmaceutical company earned $2.37 billion during the quarter, compared to analysts' expectations of $2.34 billion. Vertex Pharmaceuticals had a net margin of 35.40% and a trailing twelve-month return on equity of 25.06%. Vertex Pharmaceuticals's revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.16 earnings per share.
Read the conference call transcript.
What ETFs hold Vertex Pharmaceuticals' stock?: ETFs with the largest weight of Vertex Pharmaceuticals (NASDAQ:VRTX) stock in their portfolio include VanEck Biotech ETF (BBH), Direxion mRNA ETF (MSGR), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), Pacer US Cash Cows Growth ETF (BUL), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Biotechnology & Genome ETF (PBE) and ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA).
What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?: Vertex Pharmaceuticals updated its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.55 billion-$9.70 billion, compared to the consensus revenue estimate of $9.71 billion.
What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?: 31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).
What is Vertex Pharmaceuticals' stock symbol?: Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
Who are Vertex Pharmaceuticals' major shareholders?: Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.28%), FMR LLC (6.32%), State Street Corp (4.74%), Wellington Management Group LLP (2.92%), Price T Rowe Associates Inc. MD (2.56%) and Geode Capital Management LLC (2.10%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends.
How do I buy shares of Vertex Pharmaceuticals?: Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vertex Pharmaceuticals' stock price today?: One share of VRTX stock can currently be purchased for approximately $323.57.
How much money does Vertex Pharmaceuticals make?: Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $83.34 billion and generates $9.21 billion in revenue each year. The pharmaceutical company earns $3.32 billion in net income (profit) each year or $12.56 on an earnings per share basis.
How many employees does Vertex Pharmaceuticals have?: The company employs 4,800 workers across the globe.
Does Vertex Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., V2X, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?: Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial